首药控股上半年研发费用1.08亿元

Core Viewpoint - Shouyao Holdings (Beijing) Co., Ltd. reported a focus on the research and industrialization of innovative small molecule anti-tumor drugs, despite a net loss in the first half of 2025 [1] Financial Performance - In the first half of 2025, Shouyao Holdings achieved an operating income of 2 million yuan and a net profit attributable to shareholders of -104 million yuan [1] - Research and development expenses amounted to 108 million yuan during the same period [1] Research and Development Progress - The company made significant progress in key research areas, achieving milestone developments that align with expectations, laying a solid foundation for future product launches and commercialization [1] - Shouyao Holdings is actively expanding its academic influence and steadily advancing the construction of its industrialization base, with overall R&D and operational activities proceeding according to strategic plans [1]